Search results
Showing 46 to 60 of 102 results for dexamethasone
Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)
Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making
Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)
Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making
Evidence-based recommendations on lenalidomide (Revlimid) for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
NICE is unable to make a recommendation on melphalan flufenamide (Pepaxti) for treating relapsed or refractory multiple myeloma in adults. This is because Oncopeptides did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA968
Spinal metastases and metastatic spinal cord compression (QS56)
This quality standard covers diagnosis and management of spinal metastases and metastatic spinal cord compression. It describes high-quality care in priority areas for improvement.
View quality statements for QS56Show all sections
Sections for QS56
- Quality statements
- Quality statement 1: Information about recognising the symptoms of metastatic spinal cord compression
- Quality statement 2: Imaging and treatment plans for adults with suspected spinal metastases
- Quality statement 3: Imaging for adults with suspected metastatic spinal cord compression
- Quality statement 4: Coordinating investigations for adults with suspected metastatic spinal cord compression
- Quality statement 5: Coordinating care for adults with metastatic spinal cord compression
- Quality statement 6: Radiotherapy for metastatic spinal cord compression
- Quality statement 7: Supportive care and rehabilitation
Technology appraisal and highly specialised technologies appeals
Technology appraisal and Highly specialised technologies appeals
Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)
Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma in adults.
Drug-eluting stents for the treatment of coronary artery disease (TA152)
Evidence-based recommendations on using drug-eluting stents in adults.
Awaiting development [GID-TA11516] Expected publication date: TBC
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.
Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (TA228)
Evidence-based recommendations on bortezomib (Velcade) and thalidomide (Thalidomide Celgene) for treating multiple myeloma in adults.
Evidence-based recommendations on faricimab (Vabysmo) for diabetic macular oedema in adults.
Relugolix for treating hormone-sensitive prostate cancer (TA995)
Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.
Awaiting development [GID-TA11563] Expected publication date: TBC